Business Description
Femasys Inc
NAICS : 325414
SIC : 3841
ISIN : US31447E1055
Total Employee Number:
54Description
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.14 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.65 | |||||
Debt-to-EBITDA | -0.5 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -12.76 | |||||
Beneish M-Score | -2.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -17.2 | |||||
3-Year EBITDA Growth Rate | 23.2 | |||||
3-Year EPS without NRI Growth Rate | 19.5 | |||||
3-Year FCF Growth Rate | 19.7 | |||||
3-Year Book Growth Rate | -57.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.05 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 116.45 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.06 | |||||
9-Day RSI | 42.46 | |||||
14-Day RSI | 38.1 | |||||
3-1 Month Momentum % | -40.43 | |||||
6-1 Month Momentum % | -60.21 | |||||
12-1 Month Momentum % | -75.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.91 | |||||
Quick Ratio | 1.98 | |||||
Cash Ratio | 1.71 | |||||
Days Inventory | 2136.75 | |||||
Days Sales Outstanding | 56.84 | |||||
Days Payable | 895.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -71.3 | |||||
Shareholder Yield % | -111.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.57 | |||||
Operating Margin % | -688.26 | |||||
Net Margin % | -500.21 | |||||
EBITDA Margin % | -397.22 | |||||
FCF Margin % | -786.28 | |||||
OCF Margin % | -760.48 | |||||
ROE % | -280.06 | |||||
ROA % | -73.76 | |||||
ROIC % | -156.49 | |||||
3-Year ROIIC % | -102.87 | |||||
ROC (Joel Greenblatt) % | -158.05 | |||||
ROCE % | -121.04 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.94 | |||||
PB Ratio | 1.67 | |||||
Price-to-Tangible-Book | 1.7 | |||||
EV-to-EBIT | -1.12 | |||||
EV-to-EBITDA | -1.22 | |||||
EV-to-Revenue | 4.83 | |||||
EV-to-Forward-Revenue | 3.06 | |||||
EV-to-FCF | -0.61 | |||||
Price-to-GF-Value | 0.33 | |||||
| Price-to-Net-Current-Asset-Value | 3.87 | |||||
Earnings Yield (Greenblatt) % | -89.29 | |||||
FCF Yield % | -153.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FEMY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Femasys Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.376 | ||
| EPS (TTM) ($) | -6.526 | ||
| Beta | -6.4663 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 2.25 | ||
| Volatility % | 140.56 | ||
| 14-Day RSI | 38.1 | ||
| 14-Day ATR ($) | 0.485396 | ||
| 20-Day SMA ($) | 4.0195 | ||
| 12-1 Month Momentum % | -75.07 | ||
| 52-Week Range ($) | 3.5 - 22.2 | ||
| Shares Outstanding (Mil) | 3.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Femasys Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Femasys Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 25 days | ||
| General meeting for 2026 | 2026-06-24 09:00 | 4.01 (-1.47%) | ||
| 0.05:1 Stock Split | 2026-06-08 | 6.13 (-9.88%) | ||
| First quarter earnings results for 2026 | 2026-05-08 | 8.98 (-2.50%) | ||
| Annual report for 2025 | 2026-03-31 | 7.52 (-17.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 7.52 (-17.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 16.53 (-9.96%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 17.65 (-7.12%) | ||
| General meeting for 2025 | 2025-06-25 09:00 | 17.70 (-2.75%) |
Show
Entries
Femasys Inc Frequently Asked Questions
What is Femasys Inc(FEMY)'s stock price today?
The current price of FEMY is $4.02. The 52 week high of FEMY is $22.20 and 52 week low is $3.50.
When is next earnings date of Femasys Inc(FEMY)?
The next earnings date of Femasys Inc(FEMY) is 2026-08-07 Est..
Does Femasys Inc(FEMY) pay dividends? If so, how much?
Femasys Inc(FEMY) does not pay dividend.
Guru Commentaries on NAS:FEMY
No articles.
Press Release
Articles on Femasys Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers